KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $147.1 million.

  • Biogen's Shares Outstanding (Diluted Average) rose 82.25% to $147.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $147.1 million, marking a year-over-year increase of 82.25%. This contributed to the annual value of $147.1 million for FY2025, which is 82.25% up from last year.
  • Biogen's Shares Outstanding (Diluted Average) amounted to $147.1 million in Q4 2025, which was up 82.25% from $147.1 million recorded in Q3 2025.
  • Biogen's 5-year Shares Outstanding (Diluted Average) high stood at $152.3 million for Q1 2021, and its period low was $145.2 million during Q1 2023.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $147.2 million, with a median of $146.4 million in 2022.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first crashed by 1201.62% in 2021, then soared by 82.25% in 2025.
  • Biogen's Shares Outstanding (Diluted Average) (Quarter) stood at $149.6 million in 2021, then decreased by 2.41% to $146.0 million in 2022, then fell by 0.27% to $145.6 million in 2023, then rose by 0.21% to $145.9 million in 2024, then increased by 0.82% to $147.1 million in 2025.
  • Its last three reported values are $147.1 million in Q4 2025, $147.1 million for Q3 2025, and $146.7 million during Q2 2025.